CP 94253 hydrochloridePotent, selective 5-HT1B agonist CAS# 845861-39-4 |
- CAY10650
Catalog No.:BCC4178
CAS No.:1233706-88-1
- GSK 2830371
Catalog No.:BCC4179
CAS No.:1404456-53-6
- Varespladib (LY315920)
Catalog No.:BCC2310
CAS No.:172732-68-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 845861-39-4 | SDF | Download SDF |
PubChem ID | 11652258 | Appearance | Powder |
Formula | C15H20ClN3O | M.Wt | 293.8 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 25 mM in water and to 100 mM in DMSO | ||
Chemical Name | 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine;hydrochloride | ||
SMILES | CCCOC1=NC2=C(C=C1)NC=C2C3=CCNCC3.Cl | ||
Standard InChIKey | PIIOXKQIZCVXMD-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H19N3O.ClH/c1-2-9-19-14-4-3-13-15(18-14)12(10-17-13)11-5-7-16-8-6-11;/h3-5,10,16-17H,2,6-9H2,1H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent, selective 5-HT1B agonist (Ki values are 89, 2, 860, 49 and 1,600 nM for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT2 receptors respectively). Centrally active upon systemic administration in vivo. |
CP 94253 hydrochloride Dilution Calculator
CP 94253 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4037 mL | 17.0184 mL | 34.0368 mL | 68.0735 mL | 85.0919 mL |
5 mM | 0.6807 mL | 3.4037 mL | 6.8074 mL | 13.6147 mL | 17.0184 mL |
10 mM | 0.3404 mL | 1.7018 mL | 3.4037 mL | 6.8074 mL | 8.5092 mL |
50 mM | 0.0681 mL | 0.3404 mL | 0.6807 mL | 1.3615 mL | 1.7018 mL |
100 mM | 0.034 mL | 0.1702 mL | 0.3404 mL | 0.6807 mL | 0.8509 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Bakuchalcone
Catalog No.:BCN3201
CAS No.:84575-13-3
- Cleomiscosin C
Catalog No.:BCN4388
CAS No.:84575-10-0
- Rocaglamide
Catalog No.:BCN4387
CAS No.:84573-16-0
- PHA-767491
Catalog No.:BCC1858
CAS No.:845714-00-3
- 4-Hydroxycephalotaxine
Catalog No.:BCN4386
CAS No.:84567-08-8
- Bitopertin (R enantiomer)
Catalog No.:BCC1420
CAS No.:845614-12-2
- Bitopertin
Catalog No.:BCC1419
CAS No.:845614-11-1
- MNI-caged-D-aspartate
Catalog No.:BCC5896
CAS No.:845555-94-4
- Bedaquiline fumarate
Catalog No.:BCC5245
CAS No.:845533-86-0
- ICI 162,846
Catalog No.:BCC6808
CAS No.:84545-30-2
- Sevelamer Carbonate
Catalog No.:BCC4717
CAS No.:845273-93-0
- Varlitinib (ARRY334543)
Catalog No.:BCC3725
CAS No.:845272-21-1
- 2-Methyl-5-hydroxytryptamine hydrochloride
Catalog No.:BCC5663
CAS No.:845861-49-6
- Serrin A
Catalog No.:BCN6985
CAS No.:845959-98-0
- 5α-Androstanedione
Catalog No.:BCC8752
CAS No.:846-46-8
- Boldenone
Catalog No.:BCC8892
CAS No.:846-48-0
- Lorazepam
Catalog No.:BCC5970
CAS No.:846-49-1
- Cyclogalegigenin
Catalog No.:BCN6295
CAS No.:84605-18-5
- Fmoc-D-Val-OH
Catalog No.:BCC3573
CAS No.:84624-17-9
- Boc-Lys(Fmoc)-OH
Catalog No.:BCC3417
CAS No.:84624-27-1
- H-Lys(Fmoc)-OH
Catalog No.:BCC2984
CAS No.:84624-28-2
- Itraconazole
Catalog No.:BCC4914
CAS No.:84625-61-6
- Eurycomanone
Catalog No.:BCN2990
CAS No.:84633-29-4
- 4-Nitrobenzyl dimethylcarbamate
Catalog No.:BCN3284
CAS No.:84640-31-3
Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors.[Pubmed:10688630]
J Pharmacol Exp Ther. 2000 Mar;292(3):1111-7.
The ability of selective serotonin (5-HT) receptor agonists to reduce the extracellular concentration of 5-HT was examined in the striatum of awake, unrestrained mice by in vivo microdialysis. Systemic administration of either 8-OH-PIPAT (R-(+)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)] aminotetralin), a novel 5-HT(1A) receptor agonist, or CP 94,253, a selective 5-HT(1B) receptor agonist, resulted in significant dose-related reductions of striatal 5-HT. The effect of 8-OH-PIPAT (1.0 mg/kg) was blocked by pretreatment with WAY 100635 (0.1 mg/kg), a selective 5-HT(1A) receptor antagonist, but it was not blocked by pretreatment with GR 127935 (0.056 mg/kg), a selective 5-HT(1B/1D) receptor antagonist. The effect of CP 94,253 (1.0 mg/kg) was blocked by pretreatment with GR 127935 (0.056 mg/kg) but was not blocked by pretreatment with WAY 100635 (0.1 mg/kg). Neither WAY 100635 nor GR 127935 altered extracellular 5-HT levels at the doses that were able to completely block the effects of either 8-OH-PIPAT or CP 94,253. The present findings suggest that, on systemic administration, both 8-OH-PIPAT and CP 94,253 are potent and selective agonists at the somatodendritic 5-HT(1A) autoreceptor and terminal 5-HT(1B/1D) autoreceptor, respectively, and are each able to cause decreases in extracellular levels of 5-HT in the mouse striatum by activating a distinct set of receptors.
Aggression heightened by alcohol or social instigation in mice: reduction by the 5-HT(1B) receptor agonist CP-94,253.[Pubmed:10550489]
Psychopharmacology (Berl). 1999 Oct;146(4):391-9.
RATIONALE: Models of heightened aggression may be particularly relevant in exploring pharmacological options for the clinical treatment of aggressive and impulsive disorders. OBJECTIVES: To investigate and compare the effects of a 5-HT(1B) selective agonist, CP-94,253, on aggression that was heightened as a result of 1) social instigation or 2) alcohol treatment. METHODS: Male CFW mice were administered 1.0 g/kg EtOH and were subsequently confronted by an intruder in their home cage. In a separate experimental procedure, resident male mice were instigated to aggressive behavior by brief exposure to a provocative stimulus male. To test the hypothesis that activation of the 5-HT(1B )receptor subtype would preferentially attenuate heightened aggression, in comparison to the moderate levels of species-typical aggressive behaviors, the selective agonist, CP-94,253 (1.0-30 mg/kg, IP), and antagonists to the 5-HT(1B) (GR 127935; 10 mg/kg, IP) and the 5-HT(1A) receptor (WAY 100,635; 0.1 mg/kg IP) were used. RESULTS: CP-94,253 suppressed non-heightened aggressive behavior (ED(50)=7.2 mg/kg ). GR 127935, but not WAY 100,635 shifted the ED(50) for CP-94,253 to 14.5 mg/kg. Importantly, the anti-aggressive effects of CP-94,253 were not accompanied by locomotor sedation. Alcohol-heightened and instigation-heightened aggression were suppressed at lower doses than those necessary to suppress non-heightened aggression (ED(50)=3. 8 and 2.7 mg/kg, respectively). CONCLUSIONS: The current results support the hypothesis that activation of 5-HT(1B) receptors modulates very high levels of aggressive behavior in a pharmacologically and behaviorally specific manner.